Latest Competitive Analysis of Eli Lilly Drug Pipeline

In the first half of 2023, Eli Lilly successfully ascended to the top of global pharmaceutical market value, especially with a short-term stock price increase of nearly 50% under such a large volume. Clearly, this was not a result driven by historical performance growth, but was due to significant expectations (GLP-1+AD). 

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of Eli Lilly.

After all, there was no explosive growth in revenue and profits, while LTM P/E multiples rose from around 55x at the beginning of the year to nearly 80x.

Of course, the company's performance itself grew considerably well among major pharmaceutical companies. The neutralizing antibodies for Covid-19 did not cause a visible impact, and the main treatments led by Tirzepatide, Abemaciclib, and Empagliflozin, kept the annual revenue above 30 billion US dollars. With the strong foundation of these heavyweights, the company further revised its performance guidance upwards.

At the same time, their pipeline is still continuously advancing. In the weight loss line, the much-anticipated Tirzepatide unveiled two phase 3 clinical trial results for obesity and submitted the sNDA for this indication. The triple-target agonist Retatrutide published shocking results of a 24% weight loss within 48 weeks. The oral small molecule Orforglipron showed excellent results with a 15% weight loss in 36 weeks. 

In the AD line, Donanemab announced phase 3 clinical results and re-submitted BLA, other notable developments include the next generation BTK inhibitor Pirtobrutinib results from phase 1/phase 2 CLL trials, IL23p19 monoclonal antibody Mirikizumab's approval in Europe, and PD-1 monoclonal antibody Peresolimab's first-time results of RA indication. In addition, Eli Lilly, which has traditionally not been proactive in mergers and acquisitions, has recently made successive acquisitions of DICE's small molecule IL-17 inhibitors, Versanis' new mechanism weight loss drugs, Sigilon's engineered cell diabetes therapy, and Emergence’s ADC platform.